Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Cerus Corp (CERS) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 540,100
  • Shares Outstanding, K 102,710
  • Annual Sales, $ 34,220 K
  • Annual Income, $ -55,870 K
  • 36-Month Beta 2.06
  • Price/Sales 15.78
  • Price/Book 7.41

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.22 +18.01%
on 11/03/16
5.91 -15.74%
on 11/21/16
+0.46 (+10.18%)
since 11/02/16
3-Month
4.22 +18.01%
on 11/03/16
6.61 -24.66%
on 09/07/16
-1.38 (-21.70%)
since 09/02/16
52-Week
4.22 +18.01%
on 11/03/16
7.64 -34.82%
on 08/01/16
-0.77 (-13.39%)
since 12/02/15

Most Recent Stories

More News
Is Cerus (CERS) Stock a Solid Choice Right Now?

Cerus (CERS) is seeing solid earnings estimate revision and is well-positioned from a Zacks Industry Rank perspective.

Cerus Down 21.2% Since SmarTrend Downtrend Call (CERS)

SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on September 1st, 2016 at $6.37. In approximately 2 months, Cerus has returned 21.19% as of today's recent price of $5.02.

Cerus Corporation Reports Third Quarter 2016 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the third quarter ended September 30, 2016.

Cerus to Present at the Stephens 2016 Fall Investment Conference on November 8, 2016

Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Stephens 2016...

Biotech Stocks on Investors' Radar -- Advaxis, Cerus, Kite Pharma, and Cerulean Pharma

On Wednesday, October 26, 2016, the NASDAQ Composite ended the trading session at 5,250.27, down 0.63%; the Dow Jones Industrial Average edged 0.17% higher, to finish at 18,199.33; and the S&P 500 closed...

Cerus Has Returned 19.9% Since SmarTrend Recommendation (CERS)

SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on September 1st, 2016 at $6.37. In approximately 2 months, Cerus has returned 19.94% as of today's recent price of $5.10.

Cerus to Release Third Quarter 2016 Results on November 3, 2016

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Thursday, November 3, 2016, after the close of the stock market. The company will host a...

Cerus Down 20.7% Since SmarTrend Downtrend Call (CERS)

SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on September 1st, 2016 at $6.37. In approximately 1 month, Cerus has returned 20.72% as of today's recent price of $5.05.

Cerus Announces First U.S. Blood Center Customer Submits Biologics License Application to the FDA to Allow for Interstate Export of INTERCEPT Platelet Components

Cerus Corporation (NASDAQ:CERS) announced today that The Community Blood Center (CBC) of Appleton, Wisconsin has submitted the first Biologics License Application (BLA) to the U.S. Food and...

Cerus Announces that Hemolife Fundacion Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System

Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that Hemolife Fundacion Banco Nacional de Sangre (Hemolife)...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company...

See More

Support & Resistance

2nd Resistance Point 5.26
1st Resistance Point 5.12
Last Price 4.98
1st Support Level 4.86
2nd Support Level 4.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.